141 related articles for article (PubMed ID: 35259486)
1. Inadequate health-related quality of life assessment and reporting in phase III clinical trials of immune checkpoint inhibitors in solid cancers: A systematic review.
Servetto A; Salomone F; Di Costanzo F; Iuliano R; Marandino L; Napolitano F; Santaniello A; De Placido P; De Placido S; Di Maio M; Formisano L; Bianco R
Crit Rev Oncol Hematol; 2022 Apr; 172():103649. PubMed ID: 35259486
[TBL] [Abstract][Full Text] [Related]
2. Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016.
Marandino L; La Salvia A; Sonetto C; De Luca E; Pignataro D; Zichi C; Di Stefano RF; Ghisoni E; Lombardi P; Mariniello A; Reale ML; Trevisi E; Leone G; Muratori L; Marcato M; Bironzo P; Novello S; Aglietta M; Scagliotti GV; Perrone F; Di Maio M
Ann Oncol; 2018 Dec; 29(12):2288-2295. PubMed ID: 30304498
[TBL] [Abstract][Full Text] [Related]
3. Analysis of Health-Related Quality of Life Reporting in Phase III RCTs of Advanced Genitourinary Tumors.
Di Costanzo F; Napolitano F; Salomone F; Amato AR; Alberico G; Migliaccio F; Pecoraro G; Marra A; Crocetto F; Ruffo A; Scagliarini S; Rossetti S; Puglia L; Di Napoli M; Bianco R; Servetto A; Formisano L
Cancers (Basel); 2023 Dec; 15(23):. PubMed ID: 38067406
[TBL] [Abstract][Full Text] [Related]
4. Health-related quality of life is underestimated and underreported in phase III clinical trials in NSCLC.
Salomone F; Di Costanzo F; Pecoraro G; Viscardi G; Viggiano A; Napolitano F; Santaniello A; Formisano L; Bianco R; Servetto A
Lung Cancer; 2022 Dec; 174():36-44. PubMed ID: 36302311
[TBL] [Abstract][Full Text] [Related]
5. Quality of life analysis in lung cancer: A systematic review of phase III trials published between 2012 and 2018.
Reale ML; De Luca E; Lombardi P; Marandino L; Zichi C; Pignataro D; Ghisoni E; Di Stefano RF; Mariniello A; Trevisi E; Leone G; Muratori L; La Salvia A; Sonetto C; Bironzo P; Aglietta M; Novello S; Scagliotti GV; Perrone F; Di Maio M
Lung Cancer; 2020 Jan; 139():47-54. PubMed ID: 31734586
[TBL] [Abstract][Full Text] [Related]
6. Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: A systematic review and meta-analysis.
Boutros A; Bruzzone M; Tanda ET; Croce E; Arecco L; Cecchi F; Pronzato P; Ceppi M; Lambertini M; Spagnolo F
Eur J Cancer; 2021 Dec; 159():154-166. PubMed ID: 34753012
[TBL] [Abstract][Full Text] [Related]
7. Quality of life assessment and reporting in colorectal cancer: A systematic review of phase III trials published between 2012 and 2018.
Lombardi P; Marandino L; De Luca E; Zichi C; Reale ML; Pignataro D; Di Stefano RF; Ghisoni E; Mariniello A; Trevisi E; Leone G; Muratori L; La Salvia A; Sonetto C; Leone F; Aglietta M; Novello S; Scagliotti GV; Perrone F; Di Maio M
Crit Rev Oncol Hematol; 2020 Feb; 146():102877. PubMed ID: 31981880
[TBL] [Abstract][Full Text] [Related]
8. The quality of reporting general safety parameters and immune-related adverse events in clinical trials of FDA-approved immune checkpoint inhibitors.
Karimian Z; Mavoungou S; Salem JE; Tubach F; Dechartres A
BMC Cancer; 2020 Nov; 20(1):1128. PubMed ID: 33225901
[TBL] [Abstract][Full Text] [Related]
9. Meta-Analysis of Quality of Life in Cancer Patients Treated With Immune Checkpoint Inhibitors.
Gonzalez BD; Eisel SL; Bowles KE; Hoogland AI; James BW; Small BJ; Sharpe S; Hyland KA; Bulls HW; Christy SM; Mansfield J; Nelson AM; Alla R; Maharaj K; Kennedy B; Lafranchise E; Williams NL; Jennewein S; Oswald LB; Postow MA; Dicker AP; Jim HSL
J Natl Cancer Inst; 2022 Jun; 114(6):808-818. PubMed ID: 34508604
[TBL] [Abstract][Full Text] [Related]
10. A Systematic Review of Health-Related Quality of Life Reporting in Ovarian Cancer Phase III Clinical Trials: Room to Improve.
Wilson MK; Friedlander ML; Joly F; Oza AM
Oncologist; 2018 Feb; 23(2):203-213. PubMed ID: 29118265
[TBL] [Abstract][Full Text] [Related]
11. Quality of patient-reported outcomes in oncology clinical trials using immune checkpoint inhibitors: A systematic review.
Malone E; Barua R; Meti N; Li X; Fazelzad R; Hansen AR
Cancer Med; 2021 Aug; 10(15):5031-5040. PubMed ID: 34184416
[TBL] [Abstract][Full Text] [Related]
12. The effect of adding immune checkpoint inhibitors on the risk of pneumonitis for solid tumours: a meta-analysis of phase III randomised controlled trials.
Fujiwara Y; Horita N; Namkoong H; Galsky MD
Eur J Cancer; 2021 Jun; 150():168-178. PubMed ID: 33906099
[TBL] [Abstract][Full Text] [Related]
13. Quality-of-Life Assessment and Reporting in Prostate Cancer: Systematic Review of Phase 3 Trials Testing Anticancer Drugs Published Between 2012 and 2018.
Marandino L; De Luca E; Zichi C; Lombardi P; Reale ML; Pignataro D; Di Stefano RF; Ghisoni E; Mariniello A; Trevisi E; Leone G; Muratori L; La Salvia A; Sonetto C; Buttigliero C; Tucci M; Aglietta M; Novello S; Scagliotti GV; Perrone F; Di Maio M
Clin Genitourin Cancer; 2019 Oct; 17(5):332-347.e2. PubMed ID: 31416754
[TBL] [Abstract][Full Text] [Related]
14. Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: a systematic review.
Rizzo A; Mollica V; Dall'Olio FG; Ricci AD; Maggio I; Marchetti A; Rosellini M; Santoni M; Ardizzoni A; Massari F
Future Oncol; 2021 Jul; 17(20):2671-2681. PubMed ID: 33880963
[TBL] [Abstract][Full Text] [Related]
15. A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors.
Chen TW; Razak AR; Bedard PL; Siu LL; Hansen AR
Ann Oncol; 2015 Sep; 26(9):1824-1829. PubMed ID: 25888611
[TBL] [Abstract][Full Text] [Related]
16. Patient-Reported Outcomes for Cancer Patients Receiving Checkpoint Inhibitors: Opportunities for Palliative Care-A Systematic Review.
Hall ET; Singhal S; Dickerson J; Gabster B; Wong HN; Aslakson RA; Schapira L;
J Pain Symptom Manage; 2019 Jul; 58(1):137-156.e1. PubMed ID: 30905677
[TBL] [Abstract][Full Text] [Related]
17. Health-related quality of life in cancer patients treated with immune checkpoint inhibitors: A systematic review on reporting of methods in randomized controlled trials.
Faury S; Foucaud J
PLoS One; 2020; 15(1):e0227344. PubMed ID: 31978145
[TBL] [Abstract][Full Text] [Related]
18. Informative censoring due to missing data in quality of life was inadequately assessed in most oncology randomized controlled trials.
Olivier T; Haslam A; Prasad V
J Clin Epidemiol; 2021 Nov; 139():80-86. PubMed ID: 34311054
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for metastatic renal cell carcinoma.
Unverzagt S; Moldenhauer I; Nothacker M; Roßmeißl D; Hadjinicolaou AV; Peinemann F; Greco F; Seliger B
Cochrane Database Syst Rev; 2017 May; 5(5):CD011673. PubMed ID: 28504837
[TBL] [Abstract][Full Text] [Related]
20. Adverse Event Reporting Quality in Cancer Clinical Trials Evaluating Immune Checkpoint Inhibitor Therapy: A Systematic Review.
Wang Y; Chen C; Du W; Zhou Y; He L; Hong S; Zhang L
Front Immunol; 2022; 13():874829. PubMed ID: 35874673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
